問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
下載
2024-04-01 - 2028-01-31
Condition/Disease
Advanced/Metastatic Solid Tumors
Test Drug
injection
Participate Sites10Sites
Not yet recruiting1Sites
Recruiting8Sites
Terminated1Sites
2024-08-15 - 2026-12-31
Metastatic Solid Tumors
Participate Sites9Sites
Not yet recruiting5Sites
Recruiting4Sites
2020-07-01 - 2026-06-30
Eosinophilic Chronic Rhinosinusitis With Nasal Polyps
肺昇朗/Fasenra
Participate Sites6Sites
Recruiting6Sites
2020-08-21 - 2029-05-31
Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer
Osimertinib (AZD9291/TAGRISSOR/泰格莎)
Participate Sites7Sites
Recruiting7Sites
2024-10-01 - 2029-09-30
Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)
injection injection
Participate Sites8Sites
2021-02-28 - 2029-12-31
2019-06-10 - 2026-09-30
A phase III, open-label, randomized study of osimertinib with or without platinum plus pemetrexed chemotherapy, as first-line treatment in patients with epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non-small cell lung cancer (FLAURA2)
Osimertinib (AZD9291/TAGRISSO®)
Participate Sites13Sites
Recruiting9Sites
Terminated4Sites
2018-11-02 - 2028-12-31
Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer
Durvalumab (MEDI4736)
Terminated3Sites
Division of Thoracic Medicine
2020-05-12 - 2025-12-31
Completely Resected Stage II-III NSCLC
Durvalumab Durvalumab
Not yet recruiting6Sites
Recruiting2Sites
2021-03-16 - 2029-12-31
AZD9833 AZD9833 is being developed for treatment of ER-positive, HER2-negative breast cancer. Anastrozole Arimidex is indicated for the: -Treatment of hormone receptor-positive advanced breast cancer in postmenopausal women. -Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women. -Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen. Palbociclib IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer: -in combination with an aromatase inhibitor; -in combination with fulvestrant in women who have received prior endocrine therapy (see section 5.1). In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.
AZD9833 ArimidexR IbranceR
全部
